Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 19/20 | 0.67 |
| ▸ | PLA2G7 | Q13093 | 4/20 | 0.52 |
| ▸ | ABHD6 | Q9BV23 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28699405 | 0.89 | MGLL (0.68) | MGLLPLA2G7ABHD6 | |
| SCHEMBL20137036 | 0.87 | MGLL (0.68) | MGLLPLA2G7ABHD6 | |
| SCHEMBL20136974 | 0.87 | MGLL (0.65) | MGLLPLA2G7ABHD6 | |
| SCHEMBL20137069 | 0.85 | MGLL (0.66) | MGLLPLA2G7ABHD6 | |
| SCHEMBL20137130 | 0.83 | MGLL (0.71) | MGLLPLA2G7ABHD6 | |
| SCHEMBL20137134 | 0.83 | MGLL (0.67) | MGLLPLA2G7ABHD6 | |
| SCHEMBL28708460 | 0.82 | MGLL (0.72) | MGLLPLA2G7ABHD6 | |
| SCHEMBL20137017 | 0.81 | MGLL (0.65) | MGLLPLA2G7ABHD6 | |
| SCHEMBL20136992 | 0.80 | MGLL (0.71) | MGLLPLA2G7ABHD6 | |
| SCHEMBL20136949 | 0.80 | MGLL (0.69) | MGLLPLA2G7ABHD6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10093635-B2 | MAGL inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20180134674-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134674-A1 | MAGL INHIBITORS | MAG, MAGI3, MGLL | MGLL 3/4885PLA2G7 269/4885ABHD6 563/4885 |
| US-10093635-B2 | MAGL inhibitors | MAG, MAGI3, MGLL | MGLL 3/4885PLA2G7 269/4885ABHD6 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.